Loading the company…
Loading the company…
㈜본에스티스
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-10-11 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Seoul, founded in 2009. Industry: R&D & Professional Services. Revenue for 2025 was ₩37.3bn. It has 42 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2020-11-06 · latest registration 2021-06-10 · newest first
본 발명은 피부 보습 및 진정용 기능성 화장료 조성물에 관한 것으로, 구체적으로 실시예들은 정제된 스피큘, 세틸에틸헥사노에이트, 솔비탄스테라에이트, 사이클로펜타실록세인, 세테아릴알코올, 스테아릭애씨드, 1,2-헥산다이올 베타-글루칸, 글루타티온, 스쿠알란, 베타인, 메도우폼씨오일, 스크로오스코코에이트, 토코페릴아세테이트, 나이아신아마이드 알지닌, 카프릴릴글라이콜 및 올리브오일을 유효성분으로 포함하는, 피부 보습 및 진정용 화장료 조성물에 관한 것이다.
본 발명은 피부 주름 및 탄력 개선용 기능성 화장료 조성물에 관한 것으로, 구체적으로 실시예들은 정제된 스피큘, 글리세릴글루코사이드, 소듐하이알루로네이트, 나이아신아마이드 알지닌, 카프릴릴글라이콜, 1,2-헥산다이올 및 아데노신을 유효성분으로 포함하는, 피부 주름 및 탄력 개선용 화장료 조성물에 관한 것이다.
본 발명은, 프로방스장미꽃수; 동충하초추출물; 스위트아카시아꽃추출물, 제비꽃꽃추출물, 찔레꽃열매추출물, 및 쇠비름추출물 중에서 선택된 1종 이상; 밤부사 불가리스캘러스배양추출물, 녹차캘러스배양추출물, 은행나무캘러스배양추출물, 및 회화나무캘러스배양추출물 중에서 선택된 1종 이상; 나이아신아마이드(Niacinamide); 히알루론산(hyaluronic acid); 아데노신(adenosine); 및 펩타이드(Peptide)를 유효성분으로 포함하는 피부 주름 개선 및 미백용 화장료 조성물을 제공한다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 3 of 3 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 40.4 | 37.3 |
| Cost of sales | 16.7 | 16.5 |
| Gross profit (loss) | 23.7 | 20.8 |
| Selling, general and administrative expenses | 17.7 | 15.7 |
| Operating income (loss) | 6.1 | 5.1 |
| Non-operating income | 0.2 | 0.2 |
| Other gains | 0.1 | 0.0 |
| Finance income | 0.0 | 0.0 |
| Other | 0.0 | 0.2 |
| Non-operating expenses | 1.1 | 1.0 |
| Other losses | 0.2 | 0.2 |
| Finance costs | 0.8 | 0.7 |
| Other | 0.1 | 0.1 |
| Profit (loss) before tax | 5.1 | 4.3 |
| Income tax expense | 1.0 | 0.7 |
| Net income (loss) | 4.1 | 3.7 |
Revenue ₩37.3bn, down 7.8% YoY.
Operating margin 13.8% (prior 15.0%).
Net income ₩3.7bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-06